

1600 SECTION 1
BOX 1000
MAY 01 2001
RECEIVED
Response To Notice To File Missing Parts Of Application
Filing Date Granted (PTO-1533)(Large Entity)

Docket No.
41934.0101US

In Re Application Of: Nelson et al.

Serial No.
09/673,785

Filing Date
December 29, 2000

Examiner
N/Y/A

Group Art Unit
1653

Invention: PEPTIDE FRAGMENTS OF MURINE EPIDERMAL GROWTH FACTOR AS LAMININ RECEPTOR

TARGETS



TO THE ASSISTANT COMMISSIONER FOR PATENTS:
Box Missing Parts

This is a response to the Notice to File Missing Parts of Application - Filing Date Granted (PTO-1533) mailed on

March 23, 2001

Date

Enclosed herewith for filing are the following:

- A copy of the Notice to File Missing Parts of Application - Filing Date Granted (PTO-1533). (REQUIRED)
- An oath or declaration in compliance with 37 CFR 1.63, including residence information and identifying the application by the above Application Number and Filing Date.
- A properly signed oath or declaration in compliance with 37 CFR 1.63, identifying the application by the above Application Number and Filing Date.
- An oath or declaration in compliance with 37 CFR 1.63 listing the names of all inventors and signed by the omitted inventor(s), identifying this application by the above Application Number and Filing Date.
- A verified English translation of the non-English language application papers as originally filed. It is requested that this translation be used as the copy for examination purposes in the United States Patent and Trademark Office.
- Other (list):

Sequence Listing and a Computer Readable form of the Sequence Listing

04/25/2001 EBUBAK1 00000092 200823 09673785
01 FC:105 130.00 CH

DISK TO STICK

DATE:



**Response To Notice To File Missing Parts Of Application
Filing Date Granted (PTO-1533)(Large Entity)**

Docket No.
41934.0101US

In Re Application Of: Nelson et al.

Serial No.	Filing Date	Examiner	Group Art Unit
09/673,785	December 29, 2000	N/Y/A	1653

Invention: PEPTIDE FRAGMENTS OF MURINE EPIDERMAL GROWTH FACTOR AS LAMININ RECEPTOR TARGETS

TO THE ASSISTANT COMMISSIONER FOR PATENTS:

Box Missing Parts

Completion of application fees as calculated below:

Utility application filing fee

Design application filing fee

Total number of independent claims =

Total number of claims =

Multiple dependent claims **One dependent claim** **None**

Surcharge for late payment of filing fee and/or late filing of original declaration or oath

Petition and fee for filing by other than all the inventors or a person not the inventor

Fee for processing an application filed with a non-English language specification

Fee for processing and retention of application

Total completion of application fees

This is a request under the provisions of 37 CFR 1.136(a) to extend the period for filing a response to the above-identified Notice to File Missing Parts of Application. The requested extension is as follows (check time period desired). If an additional time extension is required, please consider this a petition therefor.

One month Two months Three months Four months Five months

from:

until:

Page

Total time extension fees

Total fees due

RECEIVED

TECH CENTER 1600/2900

MAY 9 2001


Response To Notice To File Missing Parts Of Application
Filing Date Granted (PTO-1533) (Large Entity)

Docket No.
41934.0101US

In Re Application Of: Nelson et al.

Serial No.	Filing Date	Examiner	Group Art Unit
09/673,785	December 29, 2000	N/Y/A	1653

Invention: PEPTIDE FRAGMENTS OF MURINE EPIDERMAL GROWTH FACTOR AS LAMININ RECEPTOR
TARGETS



TO THE ASSISTANT COMMISSIONER FOR PATENTS:
Box Missing Parts

The fee of \$130.00 is to be paid as follows:

- A check in the amount of the fee is enclosed.
- The Commissioner is hereby authorized to charge any fees which may be required, or credit any overpayment, to Deposit Account No. 20-0823
A duplicate copy of this sheet is enclosed.
- If an additional extension of time is required, please consider this a petition therefor and charge any additional fees which may be required to Deposit Account No. 20-0823
A duplicate copy of this sheet is enclosed.



Signature

Dated: April 19, 2001

Paul A. Lesko, Reg No. 45,364
Thompson Coburn LLP
1 Firststar Plaza
St. Louis, MO 63101
314-522-6443 Telephone
314-552-7443 Facsimile

I certify that this document and fee is being deposited on April 19, 2001 with the U.S. Postal Service as first class mail under 37 C.F.R. 1.8 and is addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231.



Signature of Person Mailing Correspondence

Paul A. Lesko, Reg No. 45,364

Typed or Printed Name of Person Mailing Correspondence


CC:

RECEIVED

MAY 01 2001

TECH CENTER 1600/2900


PATENT APPLICATION
41934.0101 US



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:) Examiner: N/Y/A
: :
Nelson et al.) Group Art Unit: 1653
: :
: :
Application No.: 09/673,785)
: :
Filed: December 29, 2000)
: :
: :
For: PEPTIDE FRAGMENTS OF)
MURINE EPIDERMAL GROWTH)
FACTOR AS LAMININ RECEPTOR)
TARGETS)

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231 on the below date (Date of Deposit).


Paul Lesko
Attorney for Applicant
Registration No. 45,364

April 11, 2001
Date

The Assistant Commissioner for Patents
Washington, D.C. 20231

**RESPONSE TO NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT
APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO
ACID DISCLOSURES**

Submitted herewith in response to the Office Communication of
March 23, 2001, please find a paper copy of the sequence listing and a computer readable
form of the sequence listing in the above-identified patent application.

The information recorded in the computer readable form is identical to the
written sequence listing.

This submission includes no new matter.

RECEIVED



MAY 01 2001

TECH CENTER 1600/2900

PATENT APPLICATION
41934.0101 US

Applicants' undersigned attorney may be reached by telephone at (314) 552-6443 or by facsimile at (314) 552-7443. All correspondence should continue to be directed to our address given below.

Respectfully submitted,

A handwritten signature in black ink, appearing to read "PAUL A. LESKO".

Paul A. Lesko
Attorney for Applicant
Registration No. 45,364
Thompson Coburn LLP
One Firststar Plaza
St. Louis, MO 63101

Attachments:

Paper copy of sequence listing
Disk with computer readable form of sequence listing
Copy of Notice from PTO



UNITED STATES DEPARTMENT OF COMMERCE
Patent and Trademark Office

Address: ASSISTANT COMMISSIONER FOR PATENTS
Washington, D.C. 20231

APPLICATION NO./ CONTROL NO.	FILING DATE	FIRST NAMED INVENTOR / PATENT IN REEXAMINATION	ATTORNEY DOCKET NO.
---------------------------------	-------------	---	---------------------



EXAMINER

ART UNIT PAPER

6

DATE MAILED:

Please find below and/or attached an Office communication concerning this application or proceeding.

Commissioner of Patents and Trademarks

This application contains sequence disclosures that are encompassed by the definitions for nucleotide and/or amino acid sequences set forth in 37 CFR 1.821(a)(1) and (a)(2). However, this application fails to comply with the requirements of 37 CFR 1.821 through 1.825 for the reason(s) set forth on the attached Notice To Comply With Requirements For Patent Applications Containing Nucleotide Sequence And/Or Amino Acid Sequence Disclosures. Applicant must comply with the requirements of the sequence rules (37 CFR 1.821 - 1.825) before the application can be examined under 35 U.S.C. §§ 131 and 132.

Applicant is given ONE MONTH from the mailing date of this communication within which to comply with the sequence rules, 37 CFR 1.821 - 1.825. Failure to comply with these requirements will result in ABANDONMENT of the application under 37 CFR 1.821(g). Extensions of time may be obtained by filing a petition accompanied by the extension fee under the provisions of 37 CFR 1.136(a). Direct the reply to the undersigned. Applicant is requested to return a copy of the attached Notice to Comply with the reply.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Chih-Min Kam whose telephone number is (703) 308-9437. The examiner can normally be reached on 8:00-4:30 from Monday to Friday. If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Christopher Low, can be reached on (703) 308-2923. The fax phone number for the organization where this application or proceeding is assigned is (703) 308-0294. Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist whose telephone number is (703) 308-0196.

Chih-Min Kam, Ph.D.
March 13, 2001

CHRISTOPHER S. F. LOW
SUPERVISORY PATENT EXAMINER
TECHNOLOGY CENTER 1600



Application No.: 0967385

**NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING
NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES**

Applicant must file the items indicated below within the time period set the Office action to which the Notice is attached to avoid abandonment under 35 U.S.C. § 133 (extensions of time may be obtained under the provisions of 37 CFR 1.136(a)).

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 C.F.R. 1.821 - 1.825 for the following reason(s):

1. This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to the final rulemaking notice published at 55 FR 18230 (May 1, 1990), and 1114 OG 29 (May 15, 1990). If the effective filing date is on or after July 1, 1998, see the final rulemaking notice published at 63 FR 29620 (June 1, 1998) and 1211 OG 82 (June 23, 1998).
2. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 C.F.R. 1.821(c).
3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e).
4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked -up "Raw Sequence Listing."
5. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A Substitute computer readable form must be submitted as required by 37 C.F.R. 1.825(d).
6. The paper copy of the "Sequence Listing" is not the same as the computer readable form of the "Sequence Listing" as required by 37 C.F.R. 1.821(e).
7. Other: See, e.g., specification pages 4, 5, 7, 10, 11, and 26

Applicant Must Provide:

- An initial or substitute computer readable form (CRF) copy of the "Sequence Listing".
- An initial or substitute paper copy of the "Sequence Listing", as well as an amendment directing its entry into the specification.
- A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g).

For questions regarding compliance to these requirements, please contact:

- For Rules Interpretation, call (703) 308-4216 or (703) 308-2923
- For CRF Submission Help, call (703) 308-4212
- For PatentIn software Program Support:
 - HELP DESK: (703) 739-8559, ext 508, M-F, 8 AM to 5 PM EST except holidays
 - Email: PATIN21HELP@uspto.gov or patin3help@uspto.gov
 - To purchase PatentIn software: (703) 306-2600

PLEASE RETURN A COPY OF THIS NOTICE WITH YOUR RESPONSE

RECEIVED

MAY 01 2001

TECH CENTER 1600/2900